ERBB2 and breast carcinoma: Unlike ER-positive luminal tumors and HER2-positive tumors that show a more favorable prognosis partially due to anti-hormone therapy responsiveness, the lack of expression of the molecular targets is associated with the highest recurrence rate and the worst overall survival rate among all the breast cancer subtypes.